1.            Lecht, S. et al. Rasagiline Exerts Neuroprotection towards Oxygen–Glucose-Deprivation/Reoxygenation-Induced GAPDH-Mediated Cell Death by Activating Akt/Nrf2 Signaling. Biomedicines 12, (2024).

2.            Merzbach, S., Hoffman, A., Lazarovici, P., Gilon, C. & Amer, R. Development of Clarstatin, a Novel Drug Lead for the Therapy of Autoimmune Uveitis. Pharmaceutics 16, (2024).

3.            Naamneh, M. S. et al. Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. Pharmaceuticals 17, (2024).

4.            Yang, C., Rubin, L., Yu, X., Lazarovici, P. & Zheng, W. Preclinical evidence using synthetic compounds and natural products indicates that AMPK represents a potential pharmacological target for the therapy of pulmonary diseases. Med. Res. Rev. 44, 1326–1369 (2024).

5.            Yang, C., Ge, L., Yu, X., Lazarovici, P. & Zheng, W. Artemisinin Confers Cytoprotection toward Hydrogen Peroxide-Induced Cell Apoptosis in Retinal Pigment Epithelial Cells in Correlation with the Increased Acetylation of Histone H4 at Lysine 8. Molecules 29, (2024).

6.            Klazas, M., Naamneh, M. S., Zheng, W. & Lazarovici, P. Gabapentin Increases Intra-Epidermal and Peptidergic Nerve Fibers Density and Alleviates Allodynia and Thermal Hyperalgesia in a Mouse Model of Acute Taxol-Induced Peripheral Neuropathy. Biomedicines 10, (2022).

7.            Jiang, Y. et al. Pharmacological therapies and drug development targeting SARS-CoV-2 infection. Cytokine Growth Factor Rev. 68, 13–24 (2022).

8.            Naamneh, M. S., Lazarovici, P. & Katzhendler, J. Ring-Opening Polymerization (ROP) of Phenylalanine Derived O-Carboxyanhydride (OCA) Using Different Mono- and Bimolecular Conjugated Catalysts and Amino or Alcohol Initiators. ACS Appl. Polym. Mater. 4, 7699–7709 (2022).

9.            Ge, L., Liu, S., Rubin, L., Lazarovici, P. & Zheng, W. Research Progress on Neuroprotection of Insulin-Like Growth Factor-1 towards Glutamate-Induced Neurotoxicity. Cells 11, (2022).

10.          Li, Q. et al. Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease. Oxid. Med. Cell. Longev. 2022, (2022).

11.          Jiang, Y. et al. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int. J. Biol. Sci. 18, 459–472 (2022).

12.          Gilon, C. et al. Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis. JACS Au 1, 2361–2376 (2021).

13.          Rubin, L. et al. Neurotrophic factors and their receptors in lung development and implications in lung diseases. Cytokine Growth Factor Rev. 59, 84–94 (2021).

14.          Gilon, C. et al. Novel humanin analogs confer neuroprotection and myoprotection to neuronal and myoblast cell cultures exposed to ischemia-like and doxorubicin-induced cell death insults. Peptides 134, (2020).

15.          Talhami, A. et al. Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs. Front. Chem. 8, (2020).

16.          Fluksman, A. et al. Integrin α2β1-Targeted Self-Assembled Nanocarriers for Tumor Bioimaging. ACS Appl. Bio Mater. 3, 6059–6070 (2020).

17.          Yan, F. et al. Pristimerin-induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway. J. Cell. Mol. Med. 24, 6208–6219 (2020).

18.          Jiang, Y., Yan, F., Feng, Z., Lazarovici, P. & Zheng, W. Signaling network of forkhead family of transcription factors (FOXO) in dietary restriction. Cells 9, (2020).

19.          Yan, F. et al. Foxo3a suppresses neuropeptide w expression in neuronal cells and in rat hypothalamus and its implication in hypothalamic-pituitary-adrenal (HPA) axis. Int. J. Biol. Sci. 16, 2775–2787 (2020).

20.          Lahiani, A. et al. Neurotropic activity and safety of methylene-cycloalkylacetate (MCA) derivative 3-(3-allyl-2-methylenecyclohexyl) propanoic acid. ACS Chem. Neurosci. 11, 2577–2589 (2020).

21.          Lazarovici, P. Snake- and spider-venom-derived toxins as lead compounds for drug development. Methods in Molecular Biology vol. 2068 3–26 (2020).

22.          Maatuf, Y., Priel, A. & Lazarovici, P. Measurements of cell death induced by snake and spider’s venoms and derived toxins. Methods in Molecular Biology vol. 2068 239–268 (2020).

23.          Lazarovici, P., Marcinkiewicz, C. & Lelkes, P. I. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists. Methods in Molecular Biology vol. 2068 205–223 (2020).

24.          Fang, J. et al. Protective mechanism of artemisinin on rat bone marrow-derived mesenchymal stem cells against apoptosis induced by hydrogen peroxide via activation of c-Raf-Erk1/2-p90rsk-CREB pathway. Stem Cell Res. Ther. 10, (2019).

25.          Lazarovici, P., Marcinkiewicz, C. & Lelkes, P. I. From snake venom’s disintegrins and C-type lectins to anti-platelet drugs. Toxins (Basel). 11, (2019).

26.          Shilo, D. et al. Tuftelin Is Required for NGF-Induced Differentiation of PC12 Cells. J. Mol. Neurosci. 68, 135–143 (2019).

27.          Li, S., Zhao, X., Lazarovici, P. & Zheng, W. Artemether Activation of AMPK/GSK3 β (ser9)/Nrf2 Signaling Confers Neuroprotection towards β- Amyloid-Induced Neurotoxicity in 3xTg Alzheimer’s Mouse Model. Oxid. Med. Cell. Longev. 2019, (2019).

28.          Peng, T. et al. Anti-inflammatory effects of traditional Chinese medicines on preclinical in vivo models of brain ischemia-reperfusion-injury: Prospects for neuroprotective drug discovery and therapy. Front. Pharmacol. 10, (2019).

29.          Tiram, G. et al. Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma. FASEB J. 32, 5835–5850 (2018).

30.          Wang, H., Xu, J., Lazarovici, P., Quirion, R. & Zheng, W. cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia. Front. Mol. Neurosci. 11, (2018).

31.          Lankri, D., Haham, D., Lahiani, A., Lazarovici, P. & Tsvelikhovsky, D. Methylene-Cycloalkylacetate (MCA) Scaffold-Based Compounds as Novel Neurotropic Agents. ACS Chem. Neurosci. 9, 691–698 (2018).

32.          Lahiani, A., Brand-Yavin, A., Yavin, E. & Lazarovici, P. Neuroprotective effects of bioactive compounds and mapk pathway modulation in “ischemia”—stressed PC12 pheochromocytoma cells. Brain Sci. 8, (2018).

33.          Gincberg, G. et al. Nerve growth factor plays a role in the neurotherapeutic effect of a CD45 + pan-hematopoietic subpopulation derived from human umbilical cord blood in a traumatic brain injury model. Cytotherapy 20, 245–261 (2018).

34.          Gincberg, G., Shohami, E., Lazarovici, P. & Elchalal, U. Human Umbilical Cord Blood CD45+ Pan-Hematopoietic Cells Induced a Neurotherapeutic Effect in Mice with Traumatic Brain Injury: Immunophenotyping, Comparison of Maternal and Neonatal Parameters, and Immunomodulation. J. Mol. Neurosci. 64, 185–199 (2018).

35.          Lazarovici, P. et al. Nerve growth factor-induced angiogenesis: 1. Endothelial cell tube formation assay. Methods in Molecular Biology vol. 1727 239–250 (2018).

36.          Lazarovici, P. et al. Nerve growth factor-induced angiogenesis: 2. The quail chorioallantoic membrane assay. Methods in Molecular Biology vol. 1727 251–259 (2018).

37.          Wang, H., Xu, J., Lazarovici, P. & Zheng, W. Dysbindin-1 involvement in the etiology of schizophrenia. Int. J. Mol. Sci. 18, (2017).

38.          Amsalem, O. et al. Solid nano-in-nanoparticles for potential delivery of siRNA. J. Control. Release 257, 144–155 (2017).

39.          Wang, H., Farhan, M., Xu, J., Lazarovici, P. & Zheng, W. The involvement of DARPP-32 in the pathophysiology of schizophrenia. Oncotarget 8, 53791–53803 (2017).

40.          Lahiani, A., Yavin, E. & Lazarovici, P. The molecular basis of toxins’ interactions with intracellular signaling via discrete portals. Toxins (Basel). 9, (2017).

41.          Geron, M. et al. Protein toxins of the Echis coloratus viper venom directly activate TRPV1. Biochim. Biophys. Acta - Gen. Subj. 1861, 615–623 (2017).

42.          Lahiani, A., Hidmi, A., Katzhendler, J., Yavin, E. & Lazarovici, P. Novel Synthetic PEGylated Conjugate of α-Lipoic Acid and Tempol Reduces Cell Death in a Neuronal PC12 Clonal Line Subjected to Ischemia. ACS Chem. Neurosci. 7, 1452–1462 (2016).

43.          Zheng, W. et al. Artemisinin conferred ERK mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult. Free Radic. Biol. Med. 97, 158–167 (2016).

44.          Stabler, C. T. et al. Enhanced Re-Endothelialization of Decellularized Rat Lungs. Tissue Eng. - Part C Methods 22, 439–450 (2016).

45.          Stabler, C. T., Lecht, S., Lazarovici, P. & Lelkes, P. I. Mesenchymal stem cells for therapeutic applications in pulmonary medicine. Br. Med. Bull. 115, 45–56 (2015).

46.          Cohen, G. et al. Enhanced Therapeutic Anti-Inflammatory Effect of Betamethasone on Topical Administration with Low-Frequency, Low-Intensity (20 kHz, 100 mW/cm2) Ultrasound Exposure on Carrageenan-Induced Arthritis in a Mouse Model. Ultrasound Med. Biol. 41, 2449–2457 (2015).

47.          Ettinger, K., Nevo, Y., Marcinkiewicz, C. & Lazarovici, P. Nerve growth factor-induced myoprotection in C2C12 muscle cells is mediated by α9β1 integrin via release of PGE2. J. Basic Clin. Physiol. Pharmacol. 26, 411–415 (2015).

48.          Ventresca, E. M. et al. Association of p75NTR and α9β1 integrin modulates NGF-dependent cellular responses. Cell. Signal. 27, 1225–1236 (2015).

49.          Wang, H. et al. IGF-1 Signaling via the PI3K/Akt Pathway Confers Neuroprotection in Human Retinal Pigment Epithelial Cells Exposed to Sodium Nitroprusside Insult. J. Mol. Neurosci. 55, 931–940 (2015).

50.          Wang, R. et al. Gardenamide A attenuated cell apoptosis induced by serum deprivation insult via the ERK1/2 and PI3K/AKT signaling pathways. Neuroscience 286, 242–250 (2015).

51.          Lahiani, A. et al. Human PLacental eXpanded (PLX) mesenchymal-like adherent stromal cells confer neuroprotection to nerve growth factor (NGF)-differentiated PC12 cells exposed to ischemia by secretion of IL-6 and VEGF. Biochim. Biophys. Acta - Mol. Cell Res. 1853, 422–430 (2015).

52.          Momic, T. et al. Vipegitide: A folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity. Drug Des. Devel. Ther. 9, 291–303 (2015).

53.          Stabler, C. T. et al. Revascularization of decellularized lung scaffolds: Principles and progress. Am. J. Physiol. - Lung Cell. Mol. Physiol. 309, L1273–L1285 (2015).

54.          Lecht, S. et al. Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki. Biochim. Biophys. Acta - Gen. Subj. 1850, 1169–1179 (2015).

55.          Galski, H. et al. Corrigendum to ‘P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway’ [Biochem. Pharmacol. 86 (2013) 584-596]. Biochem. Pharmacol. 92, 518 (2014).

56.          Cohen, G., Ettinger, K., Lecht, S., Lelkes, P. I. & Lazarovici, P. Transcriptional Down-regulation of Epidermal Growth Factor (EGF) Receptors by Nerve Growth Factor (NGF) in PC12 Cells. J. Mol. Neurosci. 54, 574–585 (2014).

57.          Arien-Zakay, H. et al. Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury. J. Neurotrauma 31, 1405–1416 (2014).

58.          Lecht, S. et al. Cytocompatibility of novel extracellular matrix protein analogs of biodegradable polyester polymers derived from α-hydroxy amino acids. J. Biomater. Sci. Polym. Ed. 25, 608–624 (2014).

59.          Momic, T. et al. Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of α1β1/α2β1 integrins with antiangiogenic activity. J. Pharmacol. Exp. Ther. 350, 506–519 (2014).

60.          Bercu, M. M. et al. Enhanced survival and neurite network formation of human umbilical cord blood neuronal progenitors in three-dimensional collagen constructs. J. Mol. Neurosci. 51, 249–261 (2013).

61.          Karatzas, A. et al. NGF promotes hemodynamic recovery in a rabbit hindlimb ischemic model through trkA- and VEGFR2-dependent Pathways. J. Cardiovasc. Pharmacol. 62, 270–277 (2013).

62.          Ettinger, K., Cohen, G., Momic, T. & Lazarovici, P. The effects of a chactoid scorpion venom and its purified toxins on rat blood pressure and mast cells histamine release. Toxins (Basel). 5, 1332–1342 (2013).

63.          Cohen, G. et al. Near infrared optical visualization of epidermal growth factor receptors levels in COLO205 colorectal cell line, orthotopic tumor in mice and human biopsies. Int. J. Mol. Sci. 14, 14669–14688 (2013).

64.          Jakubowski, P., Calvete, J. J., Eble, J. A., Lazarovici, P. & Marcinkiewicz, C. Identification of inhibitors of α2β1 integrin, members of C-lectin type proteins, in Echis sochureki venom. Toxicol. Appl. Pharmacol. 269, 34–42 (2013).

65.          Han, J., Gerstenhaber, J. A., Lazarovici, P. & Lelkes, P. I. Tissue factor activity and ECM-related gene expression in human aortic endothelial cells grown on electrospun biohybrid scaffolds. Biomacromolecules 14, 1338–1348 (2013).

66.          Arlinghaus, F. T. et al. Identification of α2β1 integrin inhibitor VP-i with anti-platelet properties in the venom of Vipera palaestinae. Toxicon 64, 96–105 (2013).

67.          Saglam, A. et al. Angioneural crosstalk in scaffolds with oriented microchannels for regenerative spinal cord injury repair. J. Mol. Neurosci. 49, 334–346 (2013).

68.          Lin, L. et al. Alimentary ‘green’ proteins as electrospun scaffolds for skin regenerative engineering. J. Tissue Eng. Regen. Med. 7, 994–1008 (2013).

69.          Galski, H. et al. P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway. Biochem. Pharmacol. 86, 584–596 (2013).

70.          Strande, J. L., Routhu, K. V, Lecht, S. & Lazarovici, P. Nerve growth factor reduces myocardial ischemia/reperfusion injury in rat hearts. J. Basic Clin. Physiol. Pharmacol. 24, 81–84 (2013).

71.          Gincberg, G., Arien-Zakay, H., Lazarovici, P. & Lelkes, P. I. Neural stem cells: Therapeutic potential for neurodegenerative diseases. Br. Med. Bull. 104, 7–19 (2012).

72.          Frohbergh, M. E. et al. Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering. Biomaterials 33, 9167–9178 (2012).

73.          Ettinger, K. et al. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cell. Signal. 24, 2378–2388 (2012).

74.          Cohen, G. et al. Bio-Imaging of Colorectal Cancer Models Using Near Infrared Labeled Epidermal Growth Factor. PLoS One 7, (2012).

75.          Lazarovici, P. et al. Multimodal neuroprotection induced by PACAP38 in Oxygen-glucose deprivation and middle cerebral artery occlusion stroke models. J. Mol. Neurosci. 48, 526–540 (2012).

76.          Wang, H. et al. Corrigendum to ‘Proline-rich Akt substrate of 40kDa (PRAS40): A novel downstream target of PI3k/Akt signaling pathway’ [Cell. Signal. 2012; 24:17-24]. Cell. Signal. 24, 2226 (2012).

77.          Momic, T. et al. Vixapatin (VP12), a C-type lectin-protein from Vipera xantina palestinae venom: Characterization as a novel anti-angiogenic compound. Toxins (Basel). 4, 862–877 (2012).

78.          Lecht, S. et al. Neuroprotective effects of nimodipine and nifedipine in the NGF-differentiated PC12 cells exposed to oxygen-glucose deprivation or trophic withdrawal. Int. J. Dev. Neurosci. 30, 465–469 (2012).

79.          Walsh, E. M. et al. Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis. Neuro. Oncol. 14, 890–901 (2012).

80.          Deutsch, D. et al. Biphasic influence of hypoxia on tuftelin expression in mouse mesenchymal C3H10T1/2 stem cells. Eur. J. Oral Sci. 119, 55–61 (2011).

81.          Momic, T. et al. Pharmacological aspects of Vipera xantina palestinae venom. Toxins (Basel). 3, 1420–1432 (2011).

82.          Portnoy, E., Lecht, S., Lazarovici, P., Danino, D. & Magdassi, S. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine Nanotechnology, Biol. Med. 7, 480–488 (2011).

83.          Arien-Zakay, H., Lecht, S., Nagler, A. & Lazarovici, P. Neuroprotection by human umbilical cord blood-derived progenitors in ischemic brain injuries. Arch. Ital. Biol. 149, 233–245 (2011).

84.          Nassar, T. et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res. 71, 3018–3028 (2011).

85.          Han, J. et al. Co-electrospun blends of PLGA, gelatin, and elastin as potential nonthrombogenic scaffolds for vascular tissue engineering. Biomacromolecules 12, 399–408 (2011).

86.          Pimton, P. et al. Fibronectin-mediated upregulation of α5β1 integrin and cell adhesion during differentiation of mouse embryonic stem cells. Cell Adhes. Migr. 5, 73–82 (2011).

87.          Leiser, Y. et al. The induction of tuftelin expression in PC12 cell line during hypoxia and NGF-induced differentiation. J. Cell. Physiol. 226, 165–172 (2011).

88.          Arien-Zakay, H., Lecht, S., Nagler, A. & Lazarovici, P. Human umbilical cord blood stem cells: Rational for use as a neuroprotectant in ischemic brain disease. Int. J. Mol. Sci. 11, 3513–3528 (2010).

89.          Finkelstein, Y. et al. Peaceful use of disastrous neurotoxicants. Neurotoxicology 31, 608–620 (2010).

90.          Lecht, S. et al. Transient signaling of Erk1/2, Akt and PLCγ induced by nerve growth factor in brain capillary endothelial cells. Vascul. Pharmacol. 53, 107–114 (2010).

91.          Arien-Zakay, H., Lazarovici, P. & Nagler, A. Tissue regeneration potential in human umbilical cord blood. Best Pract. Res. Clin. Haematol. 23, 291–303 (2010).

92.          Lecht, S., Arien-Zakay, H., Kohan, M., Lelkes, P. I. & Lazarovici, P. Angiostatic effects of K252a, a Trk inhibitor, in murine brain capillary endothelial cells. Mol. Cell. Biochem. 339, 201–213 (2010).

93.          Lecht, S. et al. Cardiac microvascular endothelial cells express and release nerve growth factor but not fibroblast growth factor-2. Vitr. Cell. Dev. Biol. - Anim. 46, 469–476 (2010).

94.          Lecht, S., Arien-Zakay, H., Marcinkiewicz, C., Lelkes, P. I. & Lazarovici, P. Nerve growth factor-induced protection of brain capillary endothelial cells exposed to oxygen-glucose deprivation involves attenuation of erk phosphorylation. J. Mol. Neurosci. 41, 183–192 (2010).

95.          Amin, R., Artmann, T. A., Artmann, G., Lazarovici, P. & Lelkes, P. I. Permeability of an In Vitro Model of Blood Brain Barrier (BBB). in 13th International Conference on Biomedical Engineering, ICBME 2008 vol. 23 81–84 (2009).

96.          Arien-Zakay, H. et al. Quantitative assessment of neuronal differentiation in three-dimensional collagen gels using enhanced green fluorescence protein expressing PC12 pheochromocytoma cells. J. Mol. Neurosci. 37, 225–237 (2009).

97.          Arien-Zakay, H. et al. Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors. Exp. Neurol. 216, 83–94 (2009).

98.          Arien-Zakay, H. et al. Interferon-γ-induced neuronal differentiation of human umbilical cord blood-derived progenitors. Leukemia 23, 1790–1800 (2009).

99.          Staniszewska, I. et al. Effect of VP12 and viperistatin on inhibition of collagen receptors-dependent melanoma metastasis. Cancer Biol. Ther. 8, 1507–1516 (2009).

100.        Ringel, I., Lecht, S., Sterin, M., Lelkes, P. I. & Lazarovici, P. 31P magnetic resonance spectroscopy of endothelial cells grown in three-dimensional matrigel construct as an enabling platform technology: II. The effect of anti-inflammatory drugs on phosphometabolite levels. Endothel. J. Endothel. Cell Res. 15, 299–307 (2008).

101.        Sterin, M., Ringel, I., Lecht, S., Lelkes, P. I. & Lazarovici, P. 31P magnetic resonance spectroscopy of endothelial cells grown in three-dimensional matrigel construct as an enabling platform technology: I. The effect of glial cells and valporic acid on phosphometabolite levels. Endothel. J. Endothel. Cell Res. 15, 288–298 (2008).

102.        Kolusheva, S., Lecht, S., Derazon, Y., Jelinek, R. & Lazarovici, P. Pardaxin, a fish toxin peptide interaction with a biomimetic phospholipid/polydiacetylene membrane assay. Peptides 29, 1620–1625 (2008).

103.        Staniszewska, I. et al. Integrin α9β1 is a receptor for nerve growth factor and other neurotrophins. J. Cell Sci. 121, 504–513 (2008).

104.        Brown, M. C. et al. Regulatory effect of nerve growth factor in α9β1 integrin-dependent progression of glioblastoma. Neuro. Oncol. 10, 968–980 (2008).

105.        Lecht, S., Haroutiunian, S., Hoffman, A. & Lazarovici, P. Rasagiline - A novel MAO B inhibitor in Parkinson’s disease therapy. Ther. Clin. Risk Manag. 3, 467–474 (2007).

106.        Arien-Zakay, H., Nagler, A., Galski, H. & Lazarovici, P. Neuronal conditioning medium and nerve growth factor induce neuronal differentiation of collagen-adherent progenitors derived from human umbilical cord blood. J. Mol. Neurosci. 32, 179–191 (2007).

107.        Brown, M. C. et al. VEGF-related protein isolated from Vipera palestinae venom, promotes angiogenesis. Growth Factors 25, 108–117 (2007).

108.        Ødegaard, E. et al. The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. Hum. Pathol. 38, 140–146 (2007).

109.        Lazarovici, P. et al. Intelligent Biomatrices and Engineered Tissue Constructs: In-Vitro Models for Drug Discovery and Toxicity Testing. in Drug Testing in vitro: Breakthroughs and Trends in Cell Culture Technology 1–51 (Wiley-VCH Verlag GmbH & Co. KGaA, 2006). doi:10.1002/9783527609611.ch1.

110.        Lipman, T., Tabakman, R. & Lazarovici, P. Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the Nerve Growth Factor-differentiated model of pheochromocytoma PC12 cells. Eur. J. Pharmacol. 549, 50–57 (2006).

111.        Galski, H., Sivan, H., Lazarovici, P. & Nagler, A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematological malignancies. Leuk. Res. 30, 1151–1158 (2006).

112.        Lazarovici, P., Marcinkiewicz, C. & Lelkes, P. I. Cross talk between the cardiovascular and nervous systems: Neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr. Pharm. Des. 12, 2609–2622 (2006).

113.        Rocha, A. S. et al. The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum. Pathol. 37, 562–568 (2006).

114.        Lazarovici, P., Gazit, A., Staniszewska, I., Marcinkiewicz, C. & Lelkes, P. I. Nerve Growth Factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothel. J. Endothel. Cell Res. 13, 51–59 (2006).

115.        Dollé, J.-P., Rezvan, A., Allen, F. D., Lazarovici, P. & Lelkes, P. I. Nerve growth factor-induced migration of endothelial cells. J. Pharmacol. Exp. Ther. 315, 1220–1227 (2005).

116.        Jiang, H. et al. Roles of Ras-Erk in apoptosis of PC12 cells induced by trophic factor withdrawal or oxidative stress. J. Mol. Neurosci. 25, 133–140 (2005).

117.        Hoke, A. et al. Questions and answers: Session X: Novel approaches to neuroprotection. Annals of the New York Academy of Sciences vol. 1053 502–504 (2005).

118.        Wiklund, L. et al. Questions and answers: Session V: Neuroprotective approaches and models. Annals of the New York Academy of Sciences vol. 1053 233–236 (2005).

119.        Banik, N. et al. Questions and answers: Session II: Mechanisms of neuroprotection (1). Annals of the New York Academy of Sciences vol. 1053 99–106 (2005).

120.        Skaper, S. et al. Questions and answers: Session VIII: Mechanisms of neuroprotection (2). Annals of the New York Academy of Sciences vol. 1053 405–406 (2005).

121.        Tabakman, R. et al. Neuroprotection by NGF in the PC12 in vitro OGD model: Involvement of mitogen-activated protein kinases and gene expression. Annals of the New York Academy of Sciences vol. 1053 84–96 (2005).

122.        Jevtovic-Todorovic, V. et al. Questions and answers: Session VII: The NMDA receptor as a target for neurotoxicity and neuroprotection. Annals of the New York Academy of Sciences vol. 1053 330–333 (2005).

123.        Qi, X. et al. Questions and answers: Session VI: Neuroprotective agents and mechanisms. Annals of the New York Academy of Sciences vol. 1053 287–288 (2005).

124.        Fiskum, G. et al. Questions and answers: Session IV: Role of carnitines and other agents in neuroprotection. Annals of the New York Academy of Sciences vol. 1053 192–194 (2005).

125.        Kisiel, D. G. et al. Structural determinants of the selectivity of KTS-disintegrins for the α1β1 integrin. FEBS Lett. 577, 478–482 (2004).

126.        Davidson, B. et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44, 159–165 (2004).

127.        Tabakman, R., Jiang, H., Schaefer, E., Levine, R. A. & Lazarovici, P. Nerve growth factor pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38α and p38β activation and confers neuroprotection in the pheochromocytoma PC12 model. J. Mol. Neurosci. 22, 237–249 (2004).

128.        Tabakman, R., Jiang, H., Levine, R. A., Kohen, R. & Lazarovici, P. Apoptotic Characteristics of Cell Death and the Neuroprotective Effect of Homocarnosine on Pheochromocytoma PC12 Cells Exposed to Ischemia. J. Neurosci. Res. 75, 499–507 (2004).

129.        Flørenes, V. A. et al. Expression of activated TrkA protein in melanocytic tumors: Relationship to cell profileration and clinical outcome. Am. J. Clin. Pathol. 122, 412–420 (2004).

130.        Davidson, B. et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res. Treat. 83, 119–128 (2004).

131.        Tabakman, R., Lecht, S. & Lazarovici, P. Neuroprotection by monoamine oxidase B inhibitors: A therapeutic strategy for Parkinson’s disease? BioEssays 26, 80–90 (2004).

132.        Tabakman, R., Lecht, S., Sephanova, S., Arien-Zakay, H. & Lazarovici, P. Interactions between the cells of the immune and nervous system: Neurotrophins as neuroprotection mediators in CNS injury. Progress in Brain Research vol. 146 385–401 (2004).

133.        Davidson, B. et al. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma. Clin. Exp. Metastasis 20, 621–631 (2003).

134.        Katzir, I., Shani, J., Shabashov, D., Dagan, J. & Lazarovici, P. Establishment and characterization of pheochromocytoma tumor models expressing different levels of trkA receptors. Cancer Lett. 200, 177–185 (2003).

135.        Katzir, I. et al. Characterization of nerve growth factors (NGFs) from snake venoms by use of a novel, quantitative bioassay utilizing pheochromocytoma (PC12) cells overexpressing human trkA receptors. Toxicon 42, 481–490 (2003).

136.        Givant-Horwitz, V. et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol. Oncol. 91, 160–172 (2003).

137.        Davidson, B. et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin. Cancer Res. 9, 2248–2259 (2003).

138.        Lazarovici, P. The structure and function of pardaxin. J. Toxicol. - Toxin Rev. 21, 391–421 (2002).

139.        Bloch-Shilderman, E. et al. Pardaxin stimulation of phospholipases A2 and their involvement in exocytosis in PC-12 cells. J. Pharmacol. Exp. Ther. 301, 953–962 (2002).

140.        Vaudry, D., Stork, P. J. S., Lazarovici, P. & Eiden, L. E. Signaling pathways for PC12 cell differentiation: Making the right connections. Science (80-. ). 296, 1648–1649 (2002).

141.        Tabakman, R., Lazarovici, P. & Kohen, R. Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. J. Neurosci. Res. 68, 463–469 (2002).

142.        Abu-Raya, S., Tabakman, R., Blaugrund, E., Trembovler, V. & Lazarovici, P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol. 434, 109–116 (2002).

143.        Cantarella, G. et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J. 16, 1307–1309 (2002).

144.        Katzir, I., Shani, J., Regev, K., Shabashov, D. & Lazarovici, P. A quantitative bioassay for nerve growth factor, using PC12 clones expressing different levels of trkA receptors. J. Mol. Neurosci. 18, 251–264 (2002).

145.        Bloch-Shilderman, E., Jiang, H., Dingel, J. D. & Lazarovici, P. Pardaxin, an ionophore neurotoxin, induces PC12 cell death: Activation of stress kinases and production of reactive oxygen species. J. Nat. Toxins 11, 71–85 (2002).

146.        Chiarenza, A. et al. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res. 61, 3002–3008 (2001).

147.        Bloch-Shilderman, E., Jiang, H., Abu-Raya, S., Linial, M. & Lazarovici, P. Involvement of extracellular signal-regulated kinase (ERK) in pardaxin-induced dopamine release from PC12 cells. J. Pharmacol. Exp. Ther. 296, 704–711 (2001).

148.        Davidson, B. et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin. Cancer Res. 7, 3457–3464 (2001).

149.        Weinstock, M. et al. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Annals of the New York Academy of Sciences vol. 939 148–161 (2001).

150.        Desai, R., Peretz, A., Idelson, H., Lazarovici, P. & Attali, B. Ca2+-activated K+ channels in human leukemic Jurkat T cells. J. Biol. Chem. 275, 39954–39963 (2000).

151.        Monshipouri, M., Jiang, H. & Lazarovici, P. NGF stimulation of erk phosphorylation is impaired by a point mutation in the transmembrane domain of trkA receptor. J. Mol. Neurosci. 14, 69–76 (2000).

152.        Abu-Raya, S., Blaugrund, E., Trembovler, V. & Lazarovici, P. Rasagiline, a novel monoamine oxidase-B inhibitor with neuroprotective effects under ischemic conditions in PC12 cells. Drug Dev. Res. 50, 285–290 (2000).

153.        Moalem, G. et al. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J. Autoimmun. 15, 331–345 (2000).

154.        Abu-Raya, S. et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J. Neurosci. Res. 58, 456–463 (1999).

155.        Stein, S. et al. A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)Tat neutralizes tetanus toxin inside chromaffin cells. FEBS Lett. 458, 383–386 (1999).

156.        Jiang, H. et al. Nerve growth factor (NGF)-induced calcium influx and intracellular calcium mobilization in 3T3 cells expressing NGF receptors. J. Biol. Chem. 274, 26209–26216 (1999).

157.        Brodie, C. et al. Protein kinase C-ε plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells. Cell Growth Differ. 10, 183–191 (1999).

158.        Abu-Raya, S. et al. Characterization of pardaxin-induced dopamine release from pheochromocytoma cells: Role of calcium and eicosanoids. J. Pharmacol. Exp. Ther. 288, 399–406 (1999).

159.        Abu-Raya, S. et al. Cellular signaling in PC12 affected by pardaxin. ACS Symposium Series vol. 745 22–42 (1999).

160.        Lazarovici, P. & Donald Jr., F. Heterologous upregulation of nerve growth factor-TrkA receptors in PC12 cells by pituitary adenylate cyclase-activating polypeptide (PACAP). Mol. Cell Biol. Res. Commun. 2, 97–102 (1999).

161.        Fisher, A. et al. Novel therapeutic avenues in Alzheimer’s disease based on m1 muscarinic agonists - An unifying concept. Int. J. Geriatr. Psychopharmacol. 1, 150–157 (1998).

162.        Abu-Raya, S. et al. Pardaxin, a new pharmacological tool to stimulate the arachidonic acid cascade in PC12 cells. J. Pharmacol. Exp. Ther. 287, 889–896 (1998).

163.        Paul, Y. et al. Translocation of acylated pardaxin into cells. FEBS Lett. 440, 131–134 (1998).

164.        Adermann, K. et al. Isolation, characterization and synthesis of a novel pardaxin isoform. FEBS Lett. 435, 173–177 (1998).

165.        Shibutani, M., Lazarovici, P., Johnson, A. C., Katagiri, Y. & Guroff, G. Transcriptional down-regulation of epidermal growth factor receptors by nerve growth factor treatment of PC12 cells. J. Biol. Chem. 273, 6878–6884 (1998).

166.        Tabakman, R., Lazarovici, P., Matsuda, Y., Brodie, C. & Ovadia, H. Protein kinase C-independent selective induction of nitric oxide synthase activity in rat alveolar macrophages by staurosporine. Nitric Oxide - Biol. Chem. 2, 250–258 (1998).

167.        Lazarovici, P., Jiang, H. & Fink Jr., D. The 38-amino-acid form of pituitary adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that is dependent on protein kinase C and extracellular signal-regulated kinase but not on protein kinase A, nerve growth factor receptor tyrosine kinase, p21(ras) G protein, and pp60(c-src) cytoplasmic tyrosine kinase. Mol. Pharmacol. 54, 547–558 (1998).

168.        Ellren-Kashi, O., Trembovler, V., Abu-Raya, S., Lazarovici, P. & Shohami, E. Neuroprotective effects of gangliosides on pardaxin-induced toxicity in PC12 cells. J. Nat. Toxins 6, 285–292 (1997).

169.        Jiang, H. et al. Expression of human p140trk receptors in p140trk-deficient, PC12/endothelial cells results in nerve growth factor-induced signal transduction and DNA synthesis. J. Cell. Biochem. 66, 229–244 (1997).

170.        Lazarovici, P. et al. Down-regulation of epidermal growth factor receptors by nerve growth factor in PC12 cells is p140(trk)-, Ras-, and Src-dependent. J. Biol. Chem. 272, 11026–11034 (1997).

171.        Jiang, H. et al. Both p140(trk) and p75(NGFR) nerve growth factor receptors mediate nerve growth factor-stimulated calcium uptake. J. Biol. Chem. 272, 6835–6837 (1997).

172.        Lazarovici, P., Galski, H., Matsuda, Y. & Hochman, J. KT-5720, a new bacterial alkaloid antibiotic, reverses multidrug resistance (MDR) in lymphoma and carcinoma cells overexpressing MDR1 gene. J. Nat. Toxins 6, 19–33 (1997).

173.        Friedman, L. M., Matsuda, Y. & Lazarovici, P. The microbial alkaloid toxin staurosporine blocks the phorbol ester-induced increase in β-amyloid precursor protein in PC12 cells. Nat. Toxins 5, 173–179 (1997).

174.        Rasouly, D. et al. Staurosporine induces neurite outgrowth in neuronal hybrids (PC12EN) lacking NGF receptors. J. Cell. Biochem. 62, 356–371 (1996).

175.        Sadot, E., Heicklen-Klein, A., Barg, J., Lazarovici, P. & Ginzburg, I. Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells. J. Mol. Biol. 256, 805–812 (1996).

176.        Sadot, E., Heicklen-Klein, A., Barg, J., Lazarovici, P. & Ginzburg, I. Erratum: Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells (Journal of Molecular Biology (1995) 256 (805-812)). J. Mol. Biol. 258, 539 (1996).

177.        Shibutani, M., Kim, E., Lazarovici, P., Oshima, M. & Guroff, G. Preparation of a cell-free translation system from PC12 cells. Neurochem. Res. 21, 801–807 (1996).

178.        Lazarovici, P. et al. K252a and staurosporine microbial alkaloid toxins aS prototype of neurotropic drugs. Advances in Experimental Medicine and Biology vol. 391 367–377 (1996).

179.        Sadot, E., Barg, J., Rasouly, D., Lazarovici, P. & Ginzburg, I. Short- and long-term mechanisms of tau regulation in PC12 cells. J. Cell Sci. 108, 2857–2864 (1995).

180.        Shi, Y. L., Edwards, C. & Lazarovici, P. Ion selectivity of the channels formed by pardaxin, an lonophore, in bilayer membranes. Nat. Toxins 3, 151–155 (1995).

181.        Galski, H. et al. Kt-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug-resistant carcinoma cells. Eur. J. Cancer 31, 380–388 (1995).

182.        Rasouly, D. & Lazarovici, P. Staurosporine induces tyrosine phosphorylation of a 145 kDa protein but does not activate gp140trk in PC12 cells. Eur. J. Pharmacol. Mol. Pharmacol. 269, 255–264 (1994).

183.        Lazarovici, P. Challenging catecholamine exocytosis with pardaxin, an excitatory ionophore fish toxin. Toxin Rev. 13, 45–63 (1994).

184.        Rasouly, D. & Lazarovici, P. Staurosporine, a streptomyces alkaloid toxin as a neurotropic tool. Toxin Rev. 13, 11–23 (1994).

185.        Rasouly, D. et al. Neurites induced by staurosporine in PC12 cells are resistant to colchicine and express high levels of tau proteins. Mol. Pharmacol. 45, 29–35 (1994).

186.        Arribas, M., Blasi, J., Lazarovici, P. & Marsal, J. Calcium‐Dependent and ‐Independent Acetylcholine Release from Electric Organ Synaptosomes by Pardaxin: Evidence of a Biphasic Action of an Excitatory Neurotoxin. J. Neurochem. 60, 552–558 (1993).

187.        Raya, S. A., Trembovler, V., Shohami, E. & Lazarovici, P. Cytolysins increase intracellular calcium and induce eicosanoids release by pheochromocytoma PC12 cell cultures. Nat. Toxins 1, 263–270 (1993).

188.        Raya, S. A., Trembovler, V., Shohami, E. & Lazarovici, P. A tissue culture ischemic device to study eicosanoid release by pheochromocytoma PC12 cultures. J. Neurosci. Methods 50, 197–203 (1993).

189.        Lazarovici, P. & Lelkes, P. I. Pardaxin induces exocytosis in bovine adrenal medullary chromaffin cells independent of calcium. J. Pharmacol. Exp. Ther. 263, 1317–1326 (1992).

190.        Rasouly, D., Rahamim, E., Lester, D., Matsuda, Y. & Lazarovici, P. Staurosporine-induced neurite outgrowth in PC12 cells is independent of protein kinase C inhibition. Mol. Pharmacol. 42, 35–43 (1992).

191.        Nikodijevic, B., Nikodijevic, D. & Lazarovici, P. Pardaxin-stimulated calcium uptake in pc12 cells is blocked by cadmium and is not mediated by l-type calcium channels. J. Basic Clin. Physiol. Pharmacol. 3, 359–370 (1992).

192.        Lazarovici, P., Bergel, M., Hasson, T., Rahamim, E. & Hochman, J. Immunomagnetic separation and analysis of non‐malignant variants and parental malignant mouse lymphoma cells. J. Mol. Recognit. 4, 143–149 (1991).

193.        Hochman, J., Park, S. S., Lazarovici, P., Bergel, M. & Gottesman, M. M. Monoclonal antibodies to immunogenic lymphoma cell variants displaying impaired neoplastic properties: Characterization and applications. J. Natl. Cancer Inst. 82, 1821–1826 (1990).

194.        Lazarovici, P. Characterization and visualization of tetanus toxin acceptors on adrenal chromaffin granules. J. Physiol. (Paris). 84, 197–205 (1990).

195.        Fujita, K. et al. Preparation of affinity-purified, biotinylated tetanus toxin, and characterization and localization of cell surface binding sites on nerve growth factor-treated PC12 cells. Neurochem. Res. 15, 373–383 (1990).

196.        Lazarovici, P., Fujita, K., Contreras, M. L., DiOrio, J. P. & Lelkes, P. I. Affinity purified tetanus toxin binds to isolated chromaffin granules and inhibits catecholamine release in digitonin-permeabilized chromaffin cells. FEBS Lett. 253, 121–128 (1989).

197.        Fujita, K., Lazarovici, P. & Guroff, G. Regulation of the differentiation of PC12 pheochromocytoma cells. Environ. Health Perspect. 80, 127–142 (1989).

198.        Rudkin, B. B. et al. Cell cycle-specific action of nerve growth factor in PC12 cells: Differentiation without proliferation. EMBO J. 8, 3319–3325 (1989).

199.        Fink, D., Contreras, M. L., Lelkes, P. I. & Lazarovici, P. Staphylococcus aureus α-toxin activates phospholipases and induces a Ca2+ influx in PC12 cells. Cell. Signal. 1, 387–393 (1989).

200.        Lazarovici, P. et al. K‐252a inhibits the increase in c‐fos transcription and the increase in intracellular calcium produced by nerve growth factor in PC12 cells. J. Neurosci. Res. 23, 1–8 (1989).

201.        Shai, Y. et al. Sequencing and synthesis of pardaxin, a polypeptide from the Red Sea Moses sole with ionophore activity. FEBS Lett. 242, 161–166 (1988).

202.        Lelkes, P. I. & Lazarovici, P. Pardaxin induces aggregation but not fusion of phosphatidylserine vesicles. FEBS Lett. 230, 131–136 (1988).

203.        Koizumi, S. et al. K-252a: A specific inhibitor of the action of nerve growth factor on PC 12 cells. J. Neurosci. 8, 715–721 (1988).

204.        Lazarovici, P., Yanai, P. & Yavin, E. Molecular interactions between micellar polysialogangliosides and affinity-purified tetanotoxins in aqueous solution. J. Biol. Chem. 262, 2645–2651 (1987).

205.        Renner, P., Caratsch, C. G., Waser, P. G., Lazarovici, P. & Primor, N. Presynaptic effects of the Pardaxins, polypeptides isolated from the gland secretion of the flatfish Pardachirus marmoratus. Neuroscience 23, 319–325 (1987).

206.        Lazarovici, P. & Chan, K.-F. J. Staphylococcus aureus α-toxin. 2. Reduction of epidermal growth factor receptor affinity in PC12 cells. Toxicon 25, 637–647 (1987).

207.        Chan, K.-F. J. & Lazarovici, P. Staphylococcus aureus α-toxin. 1. Effect on protein phosphorylation in myelin. Toxicon 25, 631–636 (1987).

208.        Lazarovici, P., Dickens, G., Kuzuya, H. & Guroff, G. Long-term, heterologous down-regulation of the epidermal growth factor receptor in PC12 cells by nerve growth factor. J. Cell Biol. 104, 1611–1621 (1987).

209.        Wan, Y. Y., Orrison, B. M., Lieberman, R., Lazarovici, P. & Ozato, K. Induction of major histocompatibility class I antigens by interferons in undifferentiated F9 cells. J. Cell. Physiol. 130, 276–283 (1987).

210.        Lazarovici, P., Primor, N. & Loew, L. M. Purification and pore-forming activity of two hydrophobic polypeptides from the secretion of the Red Sea Moses sole (Pardachirus marmoratus). J. Biol. Chem. 261, 16704–16713 (1986).

211.        Lazarovici, P. & Yavin, E. Affinity-Purified Tetanus Neurotoxin Interaction with Synaptic Membranes: Properties of a Protease-Sensitive Receptor Component. Biochemistry 25, 7047–7054 (1986).

212.        Loew, L. M., Benson, L., Lazarovici, P. & Rosenberg, I. Fluorometric Analysis of Transferable Membrane Pores. Biochemistry 24, 2101–2104 (1985).

213.        Lazarovici, P. & Yavin, E. Tetanus toxin interaction with human erythrocytes. II. Kinetic properties of toxin association and evidence for a ganglioside-toxin macromolecular complex formation. BBA - Biomembr. 812, 532–542 (1985).

214.        Lazarovici, P. & Yavin, E. Tetanus toxin interaction with human erythrocytes. I. Properties of polysialoganglioside association with the cell surface. BBA - Biomembr. 812, 523–531 (1985).

215.        Lazarovici, P., Menashe, M. & Zlotkin, E. Toxicity to crustacea due to polypeptide-phospholipase interaction in the venom of a chactoid scorpion. Arch. Biochem. Biophys. 229, 270–286 (1984).

216.        Lazarovici, P., Shapira, D., Pisarev, V. & Shaaya, E. Ecdysteroid level and the change in sensitivity to a juvenile hormone analogue in Ephestia cautella larvae (Lepidoptera, Phycitidae). Arch. Insect Biochem. Physiol. 1, 409–415 (1984).

217.        Lazarovici, P., Tayot, J. L. & Yavin, E. Affinity chromatographic purification and characterization of two iodinated tetanus toxin fractions exhibiting different binding properties. Toxicon 22, 401–413 (1984).

218.        Lazarovici, P., Shapira, D. & Shaaya, E. Determination of ecdysteroid titers by a double-antibody precipitation in the tropical warehouse moth, Ephestia cautella (Lepidoptera, phycitidae). Comp. Biochem. Physiol. -- Part A Physiol. 74, 525–529 (1983).

219.        Lazarovici, P., Hochman, J., Menashe, M., Primor, N. & Zlotkin, E. The cytotoxicity of a cobra venom phospholipase to mouse lymphoma cells. Arch. Toxicol. 51, 167–173 (1982).

220.        Lester, D., Lazarovici, P., Pelhate, M. & Zlotkin, E. Purification, characterization and action of two insect toxins from the venom of the scorpion buthotus judaicus. Biochim. Biophys. Acta (BBA)/Protein Struct. Mol. 701, 370–381 (1982).

221.        Breuer, E., Deutsch, J. & Lazarovici, P. A practical synthesis of the aggregation pheromone of Tribolium castaneum and Tribolium confusum. Chem. Ind. No. 22, 907–908 (1982).

222.        Lazarovici, P., Yanai, P., Pelhate, M. & Zlotkin, E. Insect toxic components from the venom of a chactoid scorpion, Scorpio maurus palmatus (Scorpionidae). J. Biol. Chem. 257, 8397–8404 (1982).

223.        Zlotkin, E., Lester, D., Lazarovici, P. & Pelhate, M. The chemistry and axonal action of two insect toxins derived from the venom of the scorpion Buthotus judaicus. Toxicon 20, 323–331 (1982).

224.        Lazarovici, P. & Zlotkin, E. A mammal toxin derived from the venom of a chactoid scorpion. Comp. Biochem. Physiol. Part C, Comp. 71, 177–181 (1982).

225.        Primor, N. & Lazarovici, P. Pardachirus marmoratus (Red Sea flatfish) secretion and its isolated toxic fraction pardaxin: The relationship between hemolysis and ATPase inhibition. Toxicon 19, 573–578 (1981).

226.        PENER, M. P. & LAZAROVICI, P. Effect of exogenous juvenile hormones on mating behaviour and yellow colour in allatectomized adult male desert locusts. Physiol. Entomol. 4, 251–261 (1979).

227.        Lazarovici, P., Lester, D., Menashá, M., Hochman, Y. & Zlotkin, E. Phospholipases and direct lytic factors (DLFs) derived from the venom of the scorpion Scorpio maurus palmatus (Scorpionidae). Toxicon 17, 97 (1979).

228.        Lazarovici, P. & Zlotkin, E. Toxins specifically active to arthropods and mammals from the venom of the scorpion Scorpio maurus palmatus (Scorpionidae). Toxicon 17, 98 (1979).

229.        Zlotkin, E., Teitelbaum, Z., Lester, D. & Lazarovici, P. Toxins selective to insects derived from scorpion venoms. Toxicon 17, 208 (1979).

230.        Teitelbaum, Z., Lazarovici, P. & Zlotkin, E. Selective binding of the scorpion venom insect toxin to insect nervous tissue. Insect Biochem. 9, 343–346 (1979).

231.        Lazaroviçi, P. & Pener, M. P. Juvenile hormones (JHs) and completion of oöcyte development in the African migratory locust: A comparative and quantitative study. Gen. Comp. Endocrinol. 33, 434–452 (1977).

232.        Beit-Yannai, E. et al. Neuroprotection against oxidative stress by serum from heat acclimated rats. Neurosci. Lett. 254, 89–92 (1998).